Header Logo

Connection

Ajaypal Singh to Aged

Back to Details
This is a "connection" page, showing publications Ajaypal Singh has written about Aged.
Ajaypal Singh
Connection Strength
1.183
Aged
  1. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
    View in: PubMed
    Score: 0.082
  2. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
    View in: PubMed
    Score: 0.077
  3. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
    View in: PubMed
    Score: 0.077
  4. Head and neck injuries from the Boston Marathon bombing at four hospitals. Emerg Radiol. 2015 Oct; 22(5):527-32.
    View in: PubMed
    Score: 0.049
  5. Radiologic features of injuries from the Boston Marathon bombing at three hospitals. AJR Am J Roentgenol. 2014 Aug; 203(2):235-9.
    View in: PubMed
    Score: 0.046
  6. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013 May 28; 14:114.
    View in: PubMed
    Score: 0.043
  7. Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. Clin Appl Thromb Hemost. 2012 Sep; 18(5):453-61.
    View in: PubMed
    Score: 0.040
  8. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010 Feb; 77(3):239-46.
    View in: PubMed
    Score: 0.033
  9. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009 May; 53(5):751-9.
    View in: PubMed
    Score: 0.032
  10. Core biopsy with curved needle technique. AJR Am J Roentgenol. 2008 Dec; 191(6):1745-50.
    View in: PubMed
    Score: 0.031
  11. Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract. 2008; 110(4):c244-50.
    View in: PubMed
    Score: 0.031
  12. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95.
    View in: PubMed
    Score: 0.031
  13. Emergency MRI of acute pelvic pain: MR protocol with no oral contrast. Emerg Radiol. 2009 Mar; 16(2):133-41.
    View in: PubMed
    Score: 0.031
  14. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 Sep; 74(6):791-8.
    View in: PubMed
    Score: 0.030
  15. Neoplastic iliopsoas masses in oncology patients: CT findings. Abdom Imaging. 2008 Jul-Aug; 33(4):493-7.
    View in: PubMed
    Score: 0.030
  16. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 Sep; 74(6):782-90.
    View in: PubMed
    Score: 0.030
  17. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int. 2008 Sep; 74(5):679-83.
    View in: PubMed
    Score: 0.030
  18. Dropped appendicolith: CT findings and implications for management. AJR Am J Roentgenol. 2008 Mar; 190(3):707-11.
    View in: PubMed
    Score: 0.030
  19. Prevention of intravenous contrast-induced nephropathy in hospital inpatients. Crit Pathw Cardiol. 2008 Mar; 7(1):1-4.
    View in: PubMed
    Score: 0.030
  20. Imaging-guided catheter drainage of abdominal collections with fistulous pancreaticobiliary communication. AJR Am J Roentgenol. 2006 Dec; 187(6):1591-6.
    View in: PubMed
    Score: 0.027
  21. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16; 355(20):2085-98.
    View in: PubMed
    Score: 0.027
  22. Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. Transplantation. 2006 Sep 15; 82(5):612-8.
    View in: PubMed
    Score: 0.027
  23. CT appearance of acute appendagitis. AJR Am J Roentgenol. 2004 Nov; 183(5):1303-7.
    View in: PubMed
    Score: 0.024
  24. Cholecystocolonic fistula: serial CT imaging features. Emerg Radiol. 2004 Jul; 10(6):301-2.
    View in: PubMed
    Score: 0.023
  25. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-2003. A 68-year-old woman with impaired renal function. N Engl J Med. 2003 Nov 20; 349(21):2055-63.
    View in: PubMed
    Score: 0.022
  26. Bouveret's syndrome: appearance on CT and upper gastrointestinal radiography before and after stone obturation. AJR Am J Roentgenol. 2003 Sep; 181(3):828-30.
    View in: PubMed
    Score: 0.022
  27. Case 22-2019: A 65-Year-Old Woman with Weakness, Dark Urine, and Dysphagia. N Engl J Med. 2019 Jul 18; 381(3):275-283.
    View in: PubMed
    Score: 0.016
  28. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 05; 21(5):1199-1208.
    View in: PubMed
    Score: 0.016
  29. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
    View in: PubMed
    Score: 0.016
  30. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol. 2017; 46(6):488-497.
    View in: PubMed
    Score: 0.015
  31. BP in Dialysis: Results of a Pilot Study. J Am Soc Nephrol. 2018 01; 29(1):307-316.
    View in: PubMed
    Score: 0.015
  32. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017; 46(5):364-370.
    View in: PubMed
    Score: 0.015
  33. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type?2 Diabetic Patients With CKD. Am J Kidney Dis. 2017 Oct; 70(4):522-531.
    View in: PubMed
    Score: 0.014
  34. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2016 Dec; 68(6):873-881.
    View in: PubMed
    Score: 0.013
  35. Cognitive function and all-cause mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2015 Feb; 65(2):303-11.
    View in: PubMed
    Score: 0.012
  36. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
    View in: PubMed
    Score: 0.011
  37. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013 Jan 29; 80(5):471-80.
    View in: PubMed
    Score: 0.010
  38. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
    View in: PubMed
    Score: 0.010
  39. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
    View in: PubMed
    Score: 0.010
  40. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55.
    View in: PubMed
    Score: 0.009
  41. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
    View in: PubMed
    Score: 0.008
  42. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis. 2009 Sep; 54(3):498-510.
    View in: PubMed
    Score: 0.008
  43. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
    View in: PubMed
    Score: 0.008
  44. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008 Feb; 19(2):372-9.
    View in: PubMed
    Score: 0.007
  45. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol. 2007 Dec; 18(12):3184-91.
    View in: PubMed
    Score: 0.007
  46. Associations between demographic factors and provider structures on cost and length of stay for hemodialysis patients with vascular access failure. Clin J Am Soc Nephrol. 2006 May; 1(3):455-61.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.